Immune System News and Research

RSS

Researchers discover new mechanism underlying esophageal cancer

A gene thought to be associated with cancer development can be a tumor suppressor gene in mice, researchers have discovered. Understanding which genes are involved in spreading cancer could lead to future therapies.

12 Apr 2011

NCI awards MabVax with Phase II SBIR grant to develop vaccine against recurrent sarcoma

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received the Phase 2 portion of the Small Business Innovation Research Grant from the National Cancer Institute under the agency's Streamlined Non-competing Award Procedures.

11 Apr 2011

GeoVax Labs expands its HIV/AIDS vaccine program with NIAID, NIH and HVTN

GeoVax Labs, Inc., announced today that it is expanding its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health and the HIV Vaccine Trials Network.

11 Apr 2011

CINJ experts to comment on vaccine therapy and biomedical informatics

April marks National Cancer Control Awareness Month, which focuses on the importance of prevention, treatment, and research. Making significant contributions in all of these areas is The Cancer Institute of New Jersey, one of the nation's 40 Comprehensive Cancer Centers as designated by the National Cancer Institute and the only such center in New Jersey.

11 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Scientists identify new treatment to combat PFAPA syndrome in children

A preliminary study conducted by a team at the National Institutes of Health has identified a promising new treatment in children for the most common form of a rare disorder.

11 Apr 2011

Scientists identify novel mechanism to control cancer spread

Saint Louis University researchers have identified a novel mechanism to control the traffic of cells and fluid from tissues to lymphatic vessels. It may be possible to harness this mechanism to fight cancer spread from one organ to another organ and improve the effectiveness of vaccines.

11 Apr 2011

FluCide nanoviricide drug reduces overall leukocytes in lung tissue of influenza model

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide drug candidates resulted in significant reduction in lung tissue presence of leukocytes, and in particular, that of eosinophils in a lethal influenza infection animal model.

8 Apr 2011

Researchers determine age of atherosclerotic plaques using carbon dating

In a new study performed in humans, researchers from Sweden's Karolinska Institutet have determined the age of atherosclerotic plaques by taking advantage of Carbon-14 residues in the atmosphere, prevailing after the extensive atomic bomb tests in the 50ties and 60ties.

8 Apr 2011

ASBMB to honor 11 scientists with annual awards for biomedical research

The winners of the American Society for Biochemistry and Molecular Biology annual awards will give lectures at the Experimental Biology 2011 conference April 9-13 at the Walter E. Washington Convention Center in Washington, D.C.

8 Apr 2011

Long-term delivery of CNTF slows loss of visual acuity caused by geographic atrophy

A phase 2 clinical trial for the treatment of a severe form of age-related macular degeneration called geographic atrophy (GA) has become the first study to show the benefit of a therapy to slow the progression of vision loss for this disease. The results highlight the benefit of the use of a neurotrophic factor to treat GA and provide hope to nearly one million Americans suffering from GA.

8 Apr 2011

Cosmic radiation can increase risk of atherosclerosis in astronauts

Astronauts anticipate more trips to the moon and manned missions to Mars. But exposure to cosmic radiation outside the Earth's magnetic field could be detrimental to their arteries, according to a study by University of Alabama at Birmingham researchers published April 6, 2011, online in the journal Radiation Research.

8 Apr 2011

Hope4Cancer offers gentle non-invasive therapies for patients with brain tumor

Linda Roberts was puzzled when her favorite food, chocolate ice cream, suddenly did not taste good, and her prized orchids didn't smell nice either. When she began having sudden, severe headaches, she mentioned the changes in taste and smell to her doctor. After several tests, Roberts was diagnosed with a glioblastoma multiforme, the most aggressive form of brain tumor.

8 Apr 2011

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

Powerful natural formula is an effective treatment for men with prostate cancer

Researchers at Indiana University and Methodist Research Institute publish the dramatic effects of a natural formula against prostate cancer. This is the second in-depth study supporting the effectiveness of this formula against the disease.

7 Apr 2011

Softer, more specific alternative to combat inflammation

Two types of guidance molecules, the attractive and the repulsive, direct the growth of nerve cells to the actual target. The designation of these molecules also describes the exclusive function that was previously attributed to them, namely to show the growing nerve fibers the way. The fundamentally new approach to the research of Prof. Dr. Schwab and his team at the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) is the realization that these guidance molecules have an additional hitherto unknown role in the immune system.

7 Apr 2011

Pitt, UPCI researchers' cancer studies presented at AACR meeting

How do certain multiple myeloma treatment drugs cause complications? How does the immune system become dysfunctional due to cancer? How safe is a vaccine that could prevent development of precancerous colon polyps? Those are among the many questions that will be answered by researchers from the University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine during the American Association for Cancer Research 102nd Annual Meeting 2011, April 2 to 6, in Orlando, Fla.

7 Apr 2011

Roche LightCycler 480 PCR System to be used at Koch Institute for advanced cancer research

Roche announced today that the David H. Koch Institute for Integrative Cancer Research at MIT will be using the Roche LightCycler® 480 System, a real-time polymerase chain reaction (PCR) system for the analysis of gene expression and genetic variation, in advanced cancer research.

From Roche Sequencing and Life Science 7 Apr 2011